Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation

scientific article published on 18 April 2006

Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.BRAINRESBULL.2006.03.013
P698PubMed publication ID16716837
P5875ResearchGate publication ID7064569

P50authorJenny MortonQ42857576
P2093author name stringDavid Hernández-Espinosa
P433issue6
P921main subjectHuntington's diseaseQ190564
P304page(s)669-679
P577publication date2006-04-18
P1433published inBrain Research BulletinQ4955784
P1476titleCalcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation
P478volume69

Reverse relations

cites work (P2860)
Q37798463Bringing natural products into the fold - exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases
Q30462195Calcineurin activity in children with Mental handicap
Q40020558Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells
Q43071425Cyclosporine A attenuates 3-nitropropionic acid-induced Huntington-like symptoms in rats: possible nitric oxide mechanism
Q34605764Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli
Q45301226Mutant huntingtin alters Tau phosphorylation and subcellular distribution
Q37930190Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.
Q34017941Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice
Q38957994Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease.
Q36999830Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body